
Praveen Kumar Marimuthu/X
May 8, 2025, 17:11
Praveen Kumar Marimuthu highlights EMBRACE II as a new standard of care for locally advanced cervical cancer
Praveen Kumar Marimuthu, DM Resident in Medical Oncology at the Christian Medical College and Hospital, shared a post on X:
“EMBRACE II sets new SOC for ChemoRT in LA cervical cancer!
- 3-yr outcomes:
- Local control 93%
- Nodal control 91%
- Disease-specific survival 89%
- PFS 78%
- OS 87%
- G3–G5 toxicity: 9% (G4 <1%, G5 <0.2%)”
Learn more about cervical cancer on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 9, 2025, 09:15
May 9, 2025, 08:15
May 9, 2025, 07:41